# Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

> **NCT05089370** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 8 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **COMBINATION_PRODUCT:** Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab

## Key facts

- **NCT ID:** NCT05089370
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-20
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-10
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05089370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05089370, "Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05089370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*